Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses

Vaccine

Volumn 26, Issue 31, 2008, Pages 3827-3834

  Tang, Choon Kit ^a   Sheng, Kuo Ching ^a   Pouniotis, Dodie ^a   Esparon, Sandra ^a   Son, Hye Youn ^b   Kim, Chul Woo ^b   Pietersz, Geoffrey A ^a   Apostolopoulos, Vasso ^a  

^a BURNET INSTITUTE   (Australia)

^b Cancer Research Institute   (South Korea)

Author keywords

DNA; Gene delivery; Mannan; MUC1; Vaccines

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; HLA A2 ANTIGEN; INTERLEUKIN 4; MANNAN; MUCIN 1; OVALBUMIN; POLYLYSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR; TUMOR VOLUME;

ANIMALS; CA-15-3 ANTIGEN; CANCER VACCINES; CYTOKINES; HLA-A2 ANTIGEN; HUMANS; MANNANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; OXIDATION-REDUCTION; SURVIVAL ANALYSIS; VACCINES, DNA;

EID: 46149114885     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.008     Document Type: Article

References (50)

1. Molas M., Gomez-Valades A.G., Vidal-Alabro A., Miguel-Turu M., Bermudez J., Bartrons R., et al. Receptor-mediated gene transfer vectors: progress towards genetic pharmaceuticals. Curr Gene Ther 3 5 (2003) 468-485
2. Howard K.A., and Alpar H.O. The development of polyplex-based DNA vaccines. J Drug Target 10 2 (2002) 143-151
3. Wu G.Y., and Wu C.H. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J Biol Chem 262 10 (1987) 4429-4432
4. Ferkol T., Perales J.C., Mularo F., and Hanson R.W. Receptor-mediated gene transfer into macrophages. Proc Natl Acad Sci USA 93 1 (1996) 101-105
5. Liang W.W., Shi X., Deshpande D., Malanga C.J., and Rojanasakul Y. Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis. Biochim Biophys Acta 1279 2 (1996) 227-234
6. Nishikawa M., Takemura S., Yamashita F., Takakura Y., Meijer D.K., Hashida M., et al. Pharmacokinetics and in vivo gene transfer of plasmid DNA complexed with mannosylated poly(l-lysine) in mice. J Drug Target 8 1 (2000) 29-38
7. Pietersz G.A., Tang C.K., and Apostolopoulos V. Structure and design of polycationic carriers for gene delivery. Mini Rev Med Chem 6 12 (2006) 1285-1298
8. Mannisto M., Reinisalo M., Ruponen M., Honkakoski P., Tammi M., and Urtti A. Polyplex-mediated gene transfer and cell cycle: effect of carrier on cellular uptake and intracellular kinetics, and significance of glycosaminoglycans. J Gene Med 9 6 (2007) 479-487
9. Arango-Rodriguez M.L., Navarro-Quiroga I., Gonzalez-Barrios J.A., Martinez-Arguelles D.B., Bannon M.J., Kouri J., et al. Biophysical characteristics of neurotensin polyplex for in vitro and in vivo gene transfection. Biochim Biophys Acta 1760 7 (2006) 1009-1020
10. Tang C.K., Lodding J., Minigo G., Pouniotis D.S., Plebanski M., Scholzen A., et al. Mannan-mediated gene delivery for cancer immunotherapy. Immunology 120 3 (2007) 325-335
11. Apostolopoulos V., Pietersz G.A., Loveland B.E., Sandrin M.S., and McKenzie I.F. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci USA 92 22 (1995) 10128-10132
12. Apostolopoulos V., Pietersz G.A., and McKenzie I.F. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 14 9 (1996) 930-938
13. Apostolopoulos V., Karanikas V., Haurum J.S., and McKenzie I.F. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 159 11 (1997) 5211-5218
14. Apostolopoulos V., Barnes N., Pietersz G.A., and McKenzie I.F. Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine 18 27 (2000) 3174-3184
15. Apostolopoulos V., Pietersz G.A., Gordon S., Martinez-Pomares L., and McKenzie I.F. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur J Immunol 30 6 (2000) 1714-1723
16. Apostolopoulos V., Pietersz G.A., Tsibanis A., Tsikkinis A., Drakaki H., Loveland B.E., et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res 8 3 (2006) R27
17. Loveland B.E., Zhao A., White S., Gan H., Hamilton K., Xing P.X., et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 12 3 Pt 1 (2006) 869-877
18. Karanikas V., Hwang L.A., Pearson J., Ong C.S., Apostolopoulos V., Vaughan H., et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 100 11 (1997) 2783-2792
19. Karanikas V., Lodding J., Maino V.C., and McKenzie I.F. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin Cancer Res 6 3 (2000) 829-837
20. Chu Y., Xia M., Lin Y., Li A., Wang Y., Liu R., et al. Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF. Cancer Gene Ther 13 5 (2006) 510-519
21. Koido S., Kashiwaba M., Chen D., Gendler S., Kufe D., and Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 165 10 (2000) 5713-5719
22. van Leeuwen E.B., Cloosen S., Senden-Gijsbers B.L., Germeraad W.T., and Bos G.M. Transduction with a fiber-modified adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC. Cytotherapy 8 1 (2006) 36-46
23. Koido S., Hara E., Homma S., Torii A., Toyama Y., Kawahara H., et al. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin Cancer Res 11 21 (2005) 7891-7900
24. Graham R.A., Burchell J.M., Beverley P., and Taylor-Papadimitriou J. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer 65 5 (1996) 664-670
25. Fong C.L., Mok C.L., and Hui K.M. Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression. Gene Ther 13 3 (2006) 245-256
26. Snyder L.A., Goletz T.J., Gunn G.R., Shi F.F., Harris M.C., Cochlin K., et al. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Vaccine 24 16 (2006) 3340-3352
27. Cho J.A., Yeo D.J., Son H.Y., Kim H.W., Jung D.S., Ko J.K., et al. Exosomes: a new delivery system for tumor antigens in cancer immunotherapy. Int J Cancer 114 4 (2005) 613-622
28. Vitiello A., Marchesini D., Furze J., Sherman L.A., and Chesnut R.W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 173 4 (1991) 1007-1015
29. Acres B., Apostolopoulos V., Balloul J.M., Wreschner D., Xing P.X., Ali-Hadji D., et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother 48 10 (2000) 588-594
30. Xing P.X., Tjandra J.J., Stacker S.A., Teh J.G., Thompson C.H., McLaughlin P.J., et al. Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol Cell Biol 67 Pt 3 (1989) 183-195
31. Gilbert S.C., Plebanski M., Harris S.J., Allsopp C.E., Thomas R., Layton G.T., et al. A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 15 12 (1997) 1280-1284
32. Michel N., Ohlschlager P., Osen W., Freyschmidt E.J., Guthohrlein H., Kaufmann A.M., et al. T cell response to human papillomavirus 16 E7 in mice: comparison of Cr release assay, intracellular IFN-gamma production ELISPOT and tetramer staining. Intervirology 45 4-6 (2002) 290-299
33. Scheibenbogen C., Lee K.H., Mayer S., Stevanovic S., Moebius U., Herr W., et al. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 3 2 (1997) 221-226
34. Pietersz G.A., Li W., Popovski V., Caruana J.A., Apostolopoulos V., and McKenzie I.F. Parameters for using mannan-MUC1 fusion protein to induce cellular immunity. Cancer Immunol Immunother 45 6 (1998) 321-326
35. Pietersz G.A., Li W., Osinski C., Apostolopoulos V., and McKenzie I.F. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. Vaccine 18 19 (2000) 2059-2071
36. Lungwitz U., Breunig M., Blunk T., and Gopferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 60 2 (2005) 247-266
37. Wagner E. Effects of membrane-active agents in gene delivery. J Control Rel 53 1-3 (1998) 155-158
38. Botten J., Alexander J., Pasquetto V., Sidney J., Barrowman P., Ting J., et al. Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J Virol 80 17 (2006) 8351-8361
39. Komori H., Nakatsura T., Senju S., Yoshitake Y., Motomura Y., Ikuta Y., et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 12 9 (2006) 2689-2697
40. Saha A., Chatterjee S.K., Foon K.A., Celis E., and Bhattacharya-Chatterjee M. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Cancer Res 67 6 (2007) 2881-2892
41. Peng S., Trimble C., He L., Tsai Y.C., Lin C.T., Boyd D.A., et al. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Ther 13 1 (2006) 67-77
42. Johnen H., Kulbe H., and Pecher G. Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1). Cancer Immunol Immunother 50 7 (2001) 356-360
43. Plunkett T., Graham R., Correa I., Sewell R., Miles D., Burchell J., et al. Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional CD8+ and CD4+ T cells but does not require the MUC1 tandem repeat domain. Int J Cancer 109 5 (2004) 691-697
44. Kontani K., Taguchi O., Ozaki Y., Hanaoka J., Tezuka N., Sawai S., et al. Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model. Cancer Gene Ther 9 4 (2002) 330-337
45. Kamata M., Denda-Nagai K., Kubota N., Aida S., Takeda K., and Irimura T. Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases. Clin Exp Metastasis 19 8 (2002) 689-696
46. Spicer A.P., Parry G., Patton S., and Gendler S.J. Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism. J Biol Chem 266 23 (1991) 15099-15109
47. Taylor-Papadimitriou J., Burchell J.M., Plunkett T., Graham R., Correa I., Miles D., et al. MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 7 2 (2002) 209-221
48. Rowse G.J., Tempero R.M., VanLith M.L., Hollingsworth M.A., and Gendler S.J. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 58 2 (1998) 315-321
49. Shi F.F., Gunn G.R., Snyder L.A., and Goletz T.J. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases. Vaccine 25 17 (2007) 3338-3346
50. Sheng K.C., Pouniotis D.S., Wright M.D., Tang C.K., Lazoura E., Pietersz G.A., et al. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 118 3 (2006) 372-383